Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age.

ABSTRACT: 2.5 × 1010 vp Ad26.COV2.S elicited robust SARS-CoV-2-specific antibody responses in adolescents through 6 months, with acceptable safety and reactogenicity profiles. Compared with adults immunized with 5 × 1010 vp Ad26.COV2.S, adolescents had higher antibody levels, despite being vaccinated with a lower dose.

SUBMITTER: Ruiz-Guinazu J 

PROVIDER: S-EPMC11599148 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature